

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A monoclonal antibody, or binding fragment thereof, which binds specifically to an antigen on the surface of small cell lung cancer (SCLC) cells, the antigen being characterized in that

- (i) it is a single polypeptide having a molecular weight of about 200 kDa as determined by SDS-PAGE under reducing conditions;
- (ii) it is absent from human multiple myeloma cells; and
- (iii) it is glycosylated.

2. (original) The monoclonal antibody, or binding fragment thereof, according to claim 1, which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession Number selected from the group consisting of ATTC Accession No. PTA-2360 (MoAb 51.2), ATCC Accession No. PTA-2358 (MoAb 37.14) and ATCC Accession No. PTA-2357 (MoAb 109.12).

3. (original) The monoclonal antibody, or binding fragment thereof, according to claim 1, which binds specifically to an antigen on the surface of small cell lung cancer (SCLC) cells, the antigen being further characterized in that (iv) it is absent from neuroendocrine cells.

4. (original) The monoclonal antibody, or binding fragment thereof, according to claim 3, which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession Number PTA-2357 (MoAb 109.12).

5. (original) A monoclonal antibody, or binding fragment thereof, which binds specifically to an antigen on the surface of small cell lung cancer (SCLC) cells, the antigen being characterized in that

- (i) it has a molecular weight of about 35 kDa to about 50 kDa as determined by SDS-PAGE under reducing conditions;
- (ii) it is absent from human multiple myeloma cells and neuroendocrine cells; and
- (iii) it is glycosylated.

6. (original). The monoclonal antibody, or binding fragment thereof, according to claim 5, which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession Number PTA-2358 (MoAb 37.14).

7. (original) A monoclonal antibody, or binding fragment thereof, which (i) binds specifically to a conformational epitope of an antigen on the surface of small cell lung cancer (SCLC) cells, and (ii) is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2359 (MoAb 26.1).

8. (original) A monoclonal antibody, or binding fragment thereof, selected from the group consisting of (i) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2358 (MoAb 37.14), a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2360 (MoAb 51.2), or a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2357 (MoAb 109.12), which antibodies bind to a cell surface glycoprotein antigen on human small cell lung cancer cells, and (ii) antibodies that are capable of binding to the same antigenic determinant as do the monoclonal antibodies produced by the hybridoma cell lines deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2358 (MoAb 37.14), having ATCC Accession No. PTA-2360 (MoAb 51.2), or having ATCC Accession No. PTA-2357 (MoAb 109.12).

9. (original) A monoclonal antibody, or binding fragment thereof, selected from the group consisting of a monoclonal antibody produced from the hybridoma cell line deposited at

the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2360 (MoAb 51.2), a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2357 (MoAb 109.12), a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2358 (MoAb 37.14) and a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA--2359 (MoAb 26.1).

10. (original) The monoclonal antibody, or binding fragment thereof, according to claim 8, wherein the cell surface glycoprotein antigen is present on human small cell lung cancer cells and is absent from human multiple myeloma cells.

11. (original) The monoclonal antibody, or binding fragment thereof, according to claim 8, wherein the cell surface glycoprotein antigen recognized by the monoclonal antibody or binding fragment thereof is present on the surface of human small cell lung cancer cells and is a single glycosylated polypeptide having a molecular weight of about 200 kDa as determined by SDS-PAGE under reducing conditions.

12. (original) The monoclonal antibody or binding fragment thereof, according to any one of claims 1, 5, or 9, wherein the binding fragment is selected from the group consisting of Fab fragments, F(ab)₂ fragments, Fab' fragments, F(ab')₂ fragments, Fd fragments, Fd' fragments and Fv fragments.

13. (cancelled)

14. (original) A hybridoma cell line which produces a monoclonal antibody which binds specifically to an antigen on the surface of small cell lung cancer (SCLC) cells, the antigen being characterized in that

- (i) it is a single polypeptide having a molecular weight of about 200 kDa as determined by SDS-PAGE under reducing conditions;

- (ii) it is absent from human multiple myeloma cells; and
- (iii) it is glycosylated.

15. (original) The hybridoma cell line according to claim 14, which is deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2360 (MoAb 51.2).

16. (original) The hybridoma cell line according to claim 14, which is deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2357 (MoAb 109.12).

17. (original) The hybridoma cell line according to claim 14, which is deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2358 (MoAb 37.14).

18. (original) The hybridoma cell line according to claim 14, wherein the antigen on the surface of small cell lung cancer (SCLC) cells which is bound by the produced monoclonal antibody, or binding fragment thereof, is further characterized in that (iv) it is absent from neuroendocrine cells.

19. (original) The hybridoma cell line according to claim 18, which is deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2357 (MoAb 109.12).

20. (original) A hybridoma cell line which produces a monoclonal antibody which binds specifically to an antigen on the surface of small cell lung cancer (SCLC) cells, the antigen being characterized in that

- (i) it has a molecular weight of about 35 kDa to about 50 kDa as determined by SDS-PAGE under reducing conditions;

- (ii) it is absent from human multiple myeloma cells and neuroendocrine cells; and
- (iii) it is glycosylated.

21. (original) The hybridoma cell line according to claim 20, which is deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2358 (MoAb 37.14).

22. – 34. (cancelled)

35. (original) A pharmaceutical composition comprising the monoclonal antibody, or binding fragment thereof, according to any one of claims 1, 5, or 9, and a pharmaceutically acceptable carrier, excipient, or diluent.

36. (original) The pharmaceutical composition according to claim 35, wherein the monoclonal antibody, or binding fragment thereof, recognizes an antigen present on the surface of human small cell lung cancer cells, but not on normal lung cells, or on human multiple myeloma cells.

37. (original) A pharmaceutical composition comprising a monoclonal antibody, or binding fragment thereof, wherein the antibody

(a) is selected from the group consisting of (i) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession No. PTA-2360 (MoAb 51.2), (ii) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession No. PTA-2357 (MoAb 109.12); (iii) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession No. PTA-2358 (MoAb 37.14), (iv) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) and having ATCC Accession No. PTA-2359 (MoAb 26.1); wherein

the monoclonal antibodies (i)-(iv) bind to a cell surface antigen on human small cell lung cancer cells;

(b) is an antibody that is capable of binding to the same antigenic determinant as does the monoclonal antibody, or a binding fragment thereof, produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) under ATCC Accession No.PTA-2360 (MoAb 51.2), or produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2357 (MoAb 109.12), or produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2358 (MoAb 37.14), or produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) under ATCC Accession No. PTA-2359 (MoAb 26.1); and a pharmaceutically acceptable carrier, excipient, or diluent.

38. (original) The monoclonal antibody according to any one of claims 1, 5, or 9, labeled with a detectable moiety.

39. (original) The monoclonal antibody according to claim 38, wherein the detectable moiety is selected from the group consisting of a fluorophore, a chromophore, a radionuclide, a chemiluminescent agent, a bioluminescent agent and an enzyme.

40. – 48. (cancelled).

49. (original) A pharmaceutical composition comprising the monoclonal antibody, or binding fragment thereof, according to any one of claims 1, 5, or 9, and a pharmaceutically acceptable carrier, excipient, or diluent, wherein the monoclonal antibody, or binding fragment thereof, recognizes an antigen present on the surface of human pancreatic cancer cells.